Amendment No. 5 to Schedule 13D by Fresenius Medical Care AG for Humacyte, Inc.

Fresenius Medical Care AG (FME AG) filed Amendment No. 5 to its Schedule 13D for Humacyte, Inc. This amendment updates the beneficial ownership of FME AG, which now holds 18,312,735 shares of Humacyte's common stock, representing approximately 9.9% of the outstanding shares. The decrease in percentage ownership from 11.8% to 9.9% is due to an increase in the number of outstanding shares of Humacyte's common stock, not due to any disposition or acquisition of shares by FME AG or its subsidiary, Fresenius Medical Care Holdings, Inc. (FMCH). Additionally, the amendment announces the appointment of Joseph E. Turk as a member of the Management Board of FME AG, effective January 1, 2026. Turk will serve as Chief Executive Officer of the Care Enablement segment.